Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study in Healthy Subjects to Evaluate the Bioavailability of Risankizumab 150mg/mL Formulation in the 180 mg Prefilled Syringe Relative to 90mg/mL Formulation in the 90 mg Prefilled Syringe

NCT05567029 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05567029
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05567029 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study in Healthy Subjects to Evaluate the Bioavailability of Risankizumab 150mg/mL Formulation in the 180 mg Prefilled Syringe Relative to 90mg/mL Formulation in the 90 mg Prefilled Syringe
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Completed
Start date
September 28, 2022
Completion date
April 20, 2023
Enrollment
198 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers